TY - JOUR AU - Okada, H. PY - 2009 DA - 2009// TI - Immunotherapeutic approaches for glioma JO - Crit Rev Immunol VL - 29 UR - https://doi.org/10.1615/CritRevImmunol.v29.i1.10 DO - 10.1615/CritRevImmunol.v29.i1.10 ID - Okada2009 ER - TY - JOUR AU - Aguilar, L. K. AU - Arvizu, M. AU - Aguilar-Cordova, E. AU - Chiocca, E. A. PY - 2012 DA - 2012// TI - The spectrum of vaccine therapies for patients with glioblastoma multiforme JO - Curr Treat Options Oncol VL - 13 UR - https://doi.org/10.1007/s11864-012-0208-2 DO - 10.1007/s11864-012-0208-2 ID - Aguilar2012 ER - TY - JOUR AU - Ruzevick, J. AU - Jackson, C. AU - Phallen, J. AU - Lim, M. PY - 2012 DA - 2012// TI - Clinical trials with immunotherapy for high-grade glioma JO - Neurosurg Clin N Am VL - 23 UR - https://doi.org/10.1016/j.nec.2012.04.003 DO - 10.1016/j.nec.2012.04.003 ID - Ruzevick2012 ER - TY - JOUR AU - Okada, H. PY - 2011 DA - 2011// TI - Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With {alpha}-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.30.7744 DO - 10.1200/JCO.2010.30.7744 ID - Okada2011 ER - TY - JOUR AU - Kalos, M. PY - 2011 DA - 2011// TI - T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia JO - Sci Transl Med VL - 3 UR - https://doi.org/10.1126/scitranslmed.3002842 DO - 10.1126/scitranslmed.3002842 ID - Kalos2011 ER - TY - JOUR AU - Porter, D. L. AU - Levine, B. L. AU - Kalos, M. AU - Bagg, A. AU - June, C. H. PY - 2011 DA - 2011// TI - Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103849 DO - 10.1056/NEJMoa1103849 ID - Porter2011 ER - TY - JOUR AU - Brentjens, R. J. PY - 2011 DA - 2011// TI - Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-04-348540 DO - 10.1182/blood-2011-04-348540 ID - Brentjens2011 ER - TY - JOUR AU - Kochenderfer, J. N. PY - 2012 DA - 2012// TI - B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-10-384388 DO - 10.1182/blood-2011-10-384388 ID - Kochenderfer2012 ER - TY - JOUR AU - Facoetti, A. PY - 2005 DA - 2005// TI - Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2588 DO - 10.1158/1078-0432.CCR-04-2588 ID - Facoetti2005 ER - TY - CHAP AU - Yeung, J. T. PY - 2013 DA - 2013// TI - LOH in the HLA Class I region at 6p21 is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma BT - Clin Cancer Res ID - Yeung2013 ER - TY - JOUR AU - Pule, M. A. PY - 2005 DA - 2005// TI - A Chimeric T Cell Antigen Receptor that Augments Cytokine Release and Supports Clonal Expansion of Primary Human T Cells JO - Mol Ther VL - 12 UR - https://doi.org/10.1016/j.ymthe.2005.04.016 DO - 10.1016/j.ymthe.2005.04.016 ID - Pule2005 ER - TY - JOUR AU - Carpenito, C. PY - 2009 DA - 2009// TI - Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains JO - Proc Natl Acad Sci VL - 106 UR - https://doi.org/10.1073/pnas.0813101106 DO - 10.1073/pnas.0813101106 ID - Carpenito2009 ER - TY - JOUR AU - Imai, C. PY - 2004 DA - 2004// TI - Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia JO - Leukemia VL - 18 UR - https://doi.org/10.1038/sj.leu.2403302 DO - 10.1038/sj.leu.2403302 ID - Imai2004 ER - TY - JOUR AU - Moeller, M. PY - 2004 DA - 2004// TI - A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells JO - Cancer Gene Ther VL - 11 UR - https://doi.org/10.1038/sj.cgt.7700710 DO - 10.1038/sj.cgt.7700710 ID - Moeller2004 ER - TY - JOUR AU - Morgan, R. A. PY - 2010 DA - 2010// TI - Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.24 DO - 10.1038/mt.2010.24 ID - Morgan2010 ER - TY - JOUR AU - Hatanpaa, K. J. AU - Burma, S. AU - Zhao, D. AU - Habib, A. A. PY - 2010 DA - 2010// TI - Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance JO - Neoplasia VL - 12 UR - https://doi.org/10.1593/neo.10688 DO - 10.1593/neo.10688 ID - Hatanpaa2010 ER - TY - JOUR AU - Mukasa, A. PY - 2010 DA - 2010// TI - Mutant EGFR is required for maintainenece of glioma growth in vivo, and its ablation leads to escape from receptor dependence JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0914356107 DO - 10.1073/pnas.0914356107 ID - Mukasa2010 ER - TY - JOUR AU - Heimberger, A. B. AU - Suki, D. AU - Yang, D. AU - Shi, W. AU - Aldape, K. PY - 2005 DA - 2005// TI - The natural history of EGFR and EGFRvIII in glioblastoma patients JO - J Transl Med VL - 3 UR - https://doi.org/10.1186/1479-5876-3-38 DO - 10.1186/1479-5876-3-38 ID - Heimberger2005 ER - TY - JOUR AU - Heimberger, A. B. PY - 2005 DA - 2005// TI - Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-1737 DO - 10.1158/1078-0432.CCR-04-1737 ID - Heimberger2005 ER - TY - JOUR AU - Zhu, X. PY - 2010 DA - 2010// TI - Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners JO - Cancer Immunol Immunother VL - 59 UR - https://doi.org/10.1007/s00262-010-0876-3 DO - 10.1007/s00262-010-0876-3 ID - Zhu2010 ER - TY - JOUR AU - Fujita, M. PY - 2009 DA - 2009// TI - Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells–Significant Roles of CXCL10 JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-2915 DO - 10.1158/0008-5472.CAN-08-2915 ID - Fujita2009 ER - TY - JOUR AU - Nishimura, F. PY - 2006 DA - 2006// TI - Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10 JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-3825 DO - 10.1158/0008-5472.CAN-05-3825 ID - Nishimura2006 ER - TY - JOUR AU - Ueda, R. PY - 2009 DA - 2009// TI - Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1 JO - Proc Natl Acad Sci U S A VL - 106 UR - https://doi.org/10.1073/pnas.0811817106 DO - 10.1073/pnas.0811817106 ID - Ueda2009 ER - TY - JOUR AU - Kohanbash, G. AU - Okada, H. PY - 2012 DA - 2012// TI - MicroRNAs and STAT interplay JO - Semin Cancer Biol VL - 22 UR - https://doi.org/10.1016/j.semcancer.2011.12.010 DO - 10.1016/j.semcancer.2011.12.010 ID - Kohanbash2012 ER - TY - JOUR AU - Xiao, C. PY - 2008 DA - 2008// TI - Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes JO - Nat Immunol VL - 9 UR - https://doi.org/10.1038/ni1575 DO - 10.1038/ni1575 ID - Xiao2008 ER - TY - JOUR AU - Sasaki, K. PY - 2010 DA - 2010// TI - miR-17-92 expression in differentiated T cells - Implications for cancer immunotherapy JO - J Transl Med VL - 8 UR - https://doi.org/10.1186/1479-5876-8-17 DO - 10.1186/1479-5876-8-17 ID - Sasaki2010 ER - TY - JOUR AU - Stupp, R. PY - 2005 DA - 2005// TI - Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa043330 DO - 10.1056/NEJMoa043330 ID - Stupp2005 ER - TY - JOUR AU - Salaun, B. PY - 2011 DA - 2011// TI - Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets JO - J Transl Med VL - 9 UR - https://doi.org/10.1186/1479-5876-9-44 DO - 10.1186/1479-5876-9-44 ID - Salaun2011 ER - TY - JOUR AU - Wu, T. PY - 2012 DA - 2012// TI - Temporal expression of microRNA cluster miR-17-92 regulates effector and memory CD8+ T-cell differentiation JO - Proc Natl Acad Sci U S A VL - 109 UR - https://doi.org/10.1073/pnas.1207327109 DO - 10.1073/pnas.1207327109 ID - Wu2012 ER - TY - JOUR AU - Jiang, S. PY - 2011 DA - 2011// TI - Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-05-355644 DO - 10.1182/blood-2011-05-355644 ID - Jiang2011 ER - TY - JOUR AU - Olive, V. AU - Li, Q. AU - He, L. PY - 2013 DA - 2013// TI - mir-17-92: a polycistronic oncomir with pleiotropic functions JO - Immunol Rev VL - 253 UR - https://doi.org/10.1111/imr.12054 DO - 10.1111/imr.12054 ID - Olive2013 ER - TY - JOUR AU - Molitoris, J. K. AU - McColl, K. S. AU - Distelhorst, C. W. PY - 2011 DA - 2011// TI - Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17 92 contributes to the induction of Bim and initiation of apoptosis JO - Mol Endocrinol VL - 25 UR - https://doi.org/10.1210/me.2010-0402 DO - 10.1210/me.2010-0402 ID - Molitoris2011 ER - TY - JOUR AU - van Haaften, G. AU - Agami, R. PY - 2010 DA - 2010// TI - Tumorigenicity of the miR-17-92 cluster distilled JO - Genes Dev VL - 24 UR - https://doi.org/10.1101/gad.1887110 DO - 10.1101/gad.1887110 ID - van Haaften2010 ER - TY - JOUR AU - Zhao, Y. PY - 2010 DA - 2010// TI - Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-2880 DO - 10.1158/0008-5472.CAN-10-2880 ID - Zhao2010 ER - TY - JOUR AU - Morgan, R. A. PY - 2012 DA - 2012// TI - Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma JO - Hum Gene Ther VL - 23 UR - https://doi.org/10.1089/hum.2012.041 DO - 10.1089/hum.2012.041 ID - Morgan2012 ER - TY - JOUR AU - Sampson, J. H. PY - 2010 DA - 2010// TI - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.6963 DO - 10.1200/JCO.2010.28.6963 ID - Sampson2010 ER - TY - JOUR AU - Kahlon, K. S. PY - 2004 DA - 2004// TI - Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0454 DO - 10.1158/0008-5472.CAN-04-0454 ID - Kahlon2004 ER - TY - JOUR AU - Kong, S. PY - 2012 DA - 2012// TI - Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-0319 DO - 10.1158/1078-0432.CCR-12-0319 ID - Kong2012 ER - TY - JOUR AU - Ahmed, N. PY - 2010 DA - 2010// TI - HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-1322 DO - 10.1158/1078-0432.CCR-09-1322 ID - Ahmed2010 ER - TY - JOUR AU - Chow, K. K. PY - 2012 DA - 2012// TI - T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma JO - Mol Ther VL - 21 UR - https://doi.org/10.1038/mt.2012.210 DO - 10.1038/mt.2012.210 ID - Chow2012 ER - TY - JOUR AU - Schulte, A. PY - 2012 DA - 2012// TI - Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-3084 DO - 10.1158/1078-0432.CCR-11-3084 ID - Schulte2012 ER - TY - JOUR AU - Zhang, H. PY - 2007 DA - 2007// TI - 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy JO - J Immunol VL - 179 UR - https://doi.org/10.4049/jimmunol.179.7.4910 DO - 10.4049/jimmunol.179.7.4910 ID - Zhang2007 ER - TY - JOUR AU - Litterman, A. J. PY - 2013 DA - 2013// TI - Profound impairment of adaptive immune responses by alkylating chemotherapy JO - J Immunol VL - 190 UR - https://doi.org/10.4049/jimmunol.1203539 DO - 10.4049/jimmunol.1203539 ID - Litterman2013 ER - TY - JOUR AU - Sanchez-Perez, L. A. PY - 2013 DA - 2013// TI - Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0059082 DO - 10.1371/journal.pone.0059082 ID - Sanchez-Perez2013 ER - TY - JOUR AU - Hammond, L. A. PY - 1999 DA - 1999// TI - Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies JO - J Clin Oncol VL - 17 ID - Hammond1999 ER - TY - JOUR AU - Sasaki, K. PY - 2007 DA - 2007// TI - Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-3280 DO - 10.1158/0008-5472.CAN-06-3280 ID - Sasaki2007 ER - TY - JOUR AU - Zhu, X. PY - 2007 DA - 2007// TI - Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models JO - J Transl Med VL - 5 UR - https://doi.org/10.1186/1479-5876-5-10 DO - 10.1186/1479-5876-5-10 ID - Zhu2007 ER - TY - JOUR AU - Okamoto, S. PY - 1996 DA - 1996// TI - Monoclonal antibody against the fusion junction of a deletion-mutant epidermal growth factor receptor JO - Br J Cancer VL - 73 UR - https://doi.org/10.1038/bjc.1996.260 DO - 10.1038/bjc.1996.260 ID - Okamoto1996 ER - TY - JOUR AU - Nakayashiki, N. PY - 2000 DA - 2000// TI - Production of a single-chain variable fragment antibody recognizing type III mutant epidermal growth factor receptor JO - Jpn J Cancer Res VL - 91 UR - https://doi.org/10.1111/j.1349-7006.2000.tb00882.x DO - 10.1111/j.1349-7006.2000.tb00882.x ID - Nakayashiki2000 ER -